Antibody to Epstein-Barr virus-specific DNase as a marker for the early detection of nasopharyngeal carcinoma.
We have previously shown that high levels of antibody to Epstein-Barr virus (EBV)-specific DNase may be a useful marker for the early diagnosis of nasopharyngeal carcinoma (NPC). Sera from 3,368 males in an area with a high risk for the development of NPC were examined for the presence of antibody to EBV-specific DNase activity. Significant levels of the antibody were found in 430 of these sera. As a result, 32 individuals have attended the out-patient department of otolaryngology for clinical examination. Among them, one individual was found to have a stage II nasopharyngeal carcinoma. This result supports the value of determination of antibody to EBV-specific DNase as a marker for the early detection of NPC.
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D002277:Carcinoma / Q000175:diagnosis*; D003851:Deoxyribonucleases / Q000276:immunology*; D004854:Herpesvirus 4, Human / Q000201:enzymology / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000175:diagnosis*; D013624:Taiwan
D000914:Antibodies, Viral; D003851:Deoxyribonucleases